Breaking
Health Care

Japanese consortium launches quantum-AI platform for cancer immunotherapy

By Elise Dubois 2 min read
Researchers operating quantum computer.
Researchers operating quantum computer.

NEC Corporation, Taiho Pharmaceutical, the Japanese Foundation for Cancer Research (JFCR), AIST and Waseda University have been chosen for a large-scale demonstration under Japan’s post-5G information-communication R&D program managed by NEDO. The effort is titled “Development and Demonstration of a Computational and Evaluation Platform for Next-Generation Cancer Immunotherapy Using Quantum Computing Technology.”

The consortium plans to merge quantum tech, artificial intelligence, drug discovery and immunology into a platform that designs and experimentally validates neoantigens—molecules arising from cancer-specific mutations and absent in healthy tissue.

Such molecules can serve as precise targets for therapies that direct the immune system against tumor cells while sparing normal cells.

Current cancer immunotherapy, including immune checkpoint inhibitors, does not benefit every patient, prompting research into new strategies that focus on these targets. They are displayed on cell surfaces by major histocompatibility complex (MHC) molecules and can trigger antigen-specific immune responses, especially those involving CD4-positive T cells via MHC class II.

Designing effective candidates remains difficult because immune outcomes depend on amino-acid sequences, MHC class II binding and surface presentation. No systematic method currently exists to create and optimise sequences that elicit CD4-positive T-cell activity while accounting for these variables.

The project will employ a quantum system to explore the vast space of possible amino-acid combinations surrounding the core region of each candidate, aiming to pinpoint diverse options with strong immunogenic potential.

Running from September 2026 to March 2029, the initiative will use AI to predict and score immune responses, while the quantum component designs flanking sequences.

Researchers will test the resulting candidates in the lab, then feed results back into computational models to refine predictions, creating an iterative drug-discovery pipeline.

The work will run on the ABCI-Q infrastructure, which blends quantum, high-performance computing and AI, and is being built by AIST’s Global Research and Development Center for Business by Quantum-AI Technology (G-QuAT). The partners aim to accelerate drug-discovery research using Japan-developed quantum technologies.

Elise Dubois

Leave a Reply

Your email address will not be published. Required fields are marked *